Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2021

View Archived Issues

Pre-existing chromosomal instability may predict response to paclitaxel

ORAI1 behind the pathogenesis of pulmonary arterial hypertension

C-118P demonstrates antiproliferative activity in models of HCC

ARN-75039 or ARN-75041 as potent arenavirus fusion inhibitors

ASCT2 is a prognostic marker in renal cell carcinoma

Twist Bioscience and Adicet collaborate on discovery of gamma delta T-cell cancer therapies

OncoPLEX yields promising results in animal models of GBM

Repurposing ritonavir as potential disease-modifying therapy for dystonia

USAMRIID to test Navrogen's small-molecule NK cell activators against SARS-CoV-2 infection

Discovery of apigenin derivative with potential to overcome drug-resistant MET-mutant RCC

PearlRiverBio patents EGFR and HER2 mutant inhibitors

Tempest Therapeutics licenses intellectual property to cancer target from University of California

Beta Pharma presents new GTPase KRAS mutant inhibitors

vTv Therapeutics discloses glucokinase activators

SQZ announces celiac disease as first autoimmune clinical translation of TAC platform

Strong nectin-4 expression tied to poor prognosis in UTUC

Satellos reports preclinical data on drug candidate in mouse model of DMD

Kinnate presents preclinical data on next-generation pan-FGFR inhibitor KIN-3248

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...